Clinical Trial Search

Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 6.3; 2.1; 7.7; 2.4 Points seen — p=<0.0001

Primary: Objective Response Rate — 2 Participants

Primary: Change in Hemoglobin A1c (HbA1c) From Baseline — -0.05; -0.06 percent

Primary: Percentage of Participants With at Least One Adverse Event. — 113; 34 Participants

Primary: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2…

Primary: Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS) — -1.19; -1.58; -1.68; -1.63 score on a scale

Primary: Mean Percent Change From Baseline to Week 11 (Study Day 77) for Inflammatory (Papules and Pustules) Lesions. — -67.6; -71.3; -51.9 percentage of mean change from baseline

Primary: Mean Change From Baseline (Pre-Dose) in Subject-rated Reflective TNSS — -1.84; -1.71; -1.47; -0.99 score on a scale

Primary: Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 Months — 147; 140 eyes

Primary: Number of Participants Smoking-Abstinent for 7 Days, 26 Weeks Post Quit Date — 5; 1 Participants

Primary: Percent Change in Central Corneal Thickness — 4.01; 5.57 milimeters

Primary: Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance) — 33 Participants

Primary: Mean Change From Baseline in Average Lissamine Green Staining in the Study Eye — -0.65 score on a scale

Primary: Change in Serum Phosphate Levels — -.47; -1.18; -1.7; -1.98 mg/dL — p=0.012

Primary: Number of Participants With Pathologic Complete Response — 5 Participants